coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Lancing And Sompting PCN, Adur · Health Inequalities Profile

    PCN U87478 · NHS Surrey and Sussex Integrated Care Board; NHS Sussex Integrated Care Board · 3 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    29,294

    Registered population

    56.7% aged 18–64

    25.0%

    Aged 65+

    ICB 21.9% · England 17.9%

    5.7%

    Ethnic minority (non-White)

    2.2% Asian · England 9.6%

    0.0%

    In IMD quintile 1

    ICB 9.2% · England 21.0%

    0

    Core20 residents (est.)

    Resident basis; registered basis 0 · see page 3

    6,217

    Hypertension register

    +8.82% in 3 yrs · England +5.60%

    311

    SMI register

    46.1% of Adur's

    790

    COPD register

    Reviews -4.52% in 3 yrs

    Forecast to 2030

    7,467

    Hypertension patients, 2030

    +1,250 on today

    83.8%

    QRISK ≥20% on statins, 2030

    +8.26pp over 3 yrs

    6.0%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    -4.5%
    COPD and blood pressure reviews trail England.

    COPD review coverage (75.6%) changed by -4.5% (England +2.8%) and hypertension control by -2.7% (England +3.6%), which may reflect recall pressure.

    £4.50
    High lipid unit cost alongside statin gap.

    Lipid-modifying items cost £4.50 (£123,821 more than at England's £1.86 unit cost across 46,902 items), while diabetes CVD statin coverage is 79.0% (England 84.4%).

    +15.0%
    Primary prevention lipid therapy and asthma gains.

    QRISK ≥ 20% lipid therapy rose +15.0% to 63.4% (England +6.2%) and annual asthma reviews rose +9.8% (England +4.4%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Patients aged 65+ reach 25.0%, above England's 17.9% and Adur's 23.3%

    Of 29,294 registered patients, 25.0% (7,321) are aged 65+ (Adur 23.3%, NHS Sussex Integrated Care Board 21.9%, England 17.9%). Working-age adults (18-64) represent 56.7% (Adur 58.0%, England 62.7%), and 18.3% are aged 0-17 (Adur 18.7%, England 19.6%). Projected list growth to 2030 (unverified methodology) is 1.0% (Adur 0.7%, England 2.3%). Census usual residents show a 94.3% White population (Adur 93.4%, England 81.1%), leaving a 5.7% ethnic minority share. An older demographic could concentrate chronic disease management and proactive frailty reviews across primary care.

    Age profile

    0–1718.3%
    18–6456.7%
    65+25.0%

    65+: ICB 21.9%, England 17.9%

    Ethnicity

    White94.3%
    Asian2.2%
    Mixed2.0%
    Black0.8%
    Other0.7%

    Older people · falls rows are Adur local-authority (LA) data, not PCN

    MeasureLocalSouth EastEnglandPeriod
    Falls admissions, 65+, per 100,000 (Adur LA)2,1742,0181,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)84.3%82.2%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)60.1%57.8%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Adur LA)1,1479819552024/25
    Falls deaths, all ages, per 100,000 (Adur LA)14.314.014.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Registered Core20 prevalence is 0.0% and average IMD decile is 5.9

    The PCN records 0.0% of registered patients in Core20, matching Adur (0.0%) but below NHS Sussex Integrated Care Board (9.2%) and England (21.0%). Average IMD decile is 5.9 (Adur 6.6, NHS Sussex Integrated Care Board 6.1, England 5.5), and estimated Core20 residents total 0. With zero Core20 concentration, local inequality work could focus on clinical vulnerability, consistent with the PCN holding 60.4% of Adur's learning disability register (215 patients) and 46.1% of its severe mental illness register (311 patients).

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Ball Tree0.0% · 0 patients
    New Pond Row0.0% · 0 patients
    Orchard0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    311

    SMI register

    1.07% recorded prevalence

    215

    Learning disability register

    0.74% recorded prevalence

    7

    Care homes, 245 beds

    In the PCN catchment

    9.4%

    Provide unpaid care

    Adur, Census 2021

    Recorded learning disability prevalence is 0.7% (215 patients; Adur 0.5%, NHS Sussex Integrated Care Board 0.6%, England 0.6%) and severe mental illness is 1.1% (311 patients; Adur 1.0%, England 1.0%). Catchment care homes contain 245 beds across 7 sites, although resident occupancy is unconfirmed. Higher recorded prevalence may increase primary care demand for annual health checks and care planning.

    Severe mental illness: physical health checks

    Severe mental illness prevalence is 1.1% (England 1.0%). Annual physical checks reached 80.3% for blood pressure (England 83.4%) and 79.8% for BMI (England 82.1%), falling to 74.8% and 75.7% at Ball Tree Surgery.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    6,217

    Hypertension register

    +8.82%

    Register growth, 3 yrs

    Adur +5.74% · England +5.60%

    −1.25pp

    BP control, under 80

    ≤140/90 · −0.03pp aged 80+

    +1,250

    More patients by 2030

    Forecast 7,467 (25.30%)

    Hypertension case-finding and control

    Hypertension recorded prevalence is 21.4% (6,217 patients), exceeding Adur (19.2%), NHS Sussex Integrated Care Board (16.3%) and England (15.2%). Although recent blood pressure checks reach 91.6% (England 90.0%), treatment to threshold fell 2.7% between 2023 and 2025 to 69.9% (England +3.6%). In patients under 80, control fell 1.8% between 2023 and 2025 to 67.1% (England +3.2% to 67.8%), dropping to 58.6% at New Pond Row Surgery. This trend could reflect review or titration delays, which an audit of uncontrolled patients could test, particularly at New Pond Row Surgery.

    Lipids and statins

    Patients with QRISK ≥ 20% on lipid-lowering therapy rose +15.0% between 2023 and 2025 (England +6.2%) to 63.4% (England 63.6%). However, secondary prevention statin treatment in diabetes with CVD is 79.0%, trailing England (84.4%). Prioritising medication reviews could address the secondary prevention gap.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202646,902£4.50£2.42£1.86£211,059
    Cardiovascular (all), 202559,219£4.25£3.32£3.33£251,681

    In 2026, lipid-regulating prescribing cost £4.50 per item (England £1.86), spending £123,821 more than at England's unit cost across 46,902 items, alongside 6,406 items per 1,000 patients aged 65+ (England 18,056 rate). This cost indicator may reflect differing formulary mix, which a local prescribing review could test.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +9.81%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +3.56%

    Asthma prevalence, PCN 3-yr % change

    COPD prevalence is 2.7% (790 patients; England 1.9%), but reviews fell 4.5% between 2023 and 2025 (England +2.8%) to 75.6% (England 76.4%). Conversely, asthma reviews rose +9.8% between 2023 and 2025 (England +4.4%) to 63.0% (England 65.7%), leaving an unreviewed gap of about 860 patients across 2,329 registered. Childhood asthma prescribing reached 1,613 items per 1,000 aged 5–19 (England 1,488 rate). This pattern could reflect recall constraints, which a scheduling audit could test.

    Cancer register and children's immunisation

    Cancer recorded prevalence is 5.1% (1,478 patients; England 3.8%). In Q1 2025/26, 6-in-1 coverage reached 100.0% at 24 months, and MMR dose 1 reached 95.4% at age 5. However, age-5 booster coverage trailed the 95.0% target: MMR dose 2 was 93.8% (1.2 pp below target; a 1.6 pp drop from dose 1) and 4-in-1 booster was 90.8% (4.2 pp below target).

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months92.6%

    England 91.0%

    6-in-1 complete primary course at 24 months100.0%

    England 92.2%

    MMR dose 1 at 24 months95.7%

    England 88.3%

    MMR dose 2 at age 593.8%

    England 82.8%

    4-in-1 pre-school booster at age 590.8%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    58.5%

    Sussex ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~1,360

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Sussex ICBEnglandNo usable stageStaged cancers
    Prostate56.6%53.2%19%1,668
    Breast86.1%85.4%23%1,400
    Bowel49.8%47.0%26%1,133
    Lung30.3%33.8%15%1,058
    Skin cancer95.3%87.8%17%698

    In 2022, across NHS Sussex ICB, 58.5% of cancers with a known stage (4,799 of 8,209) were diagnosed at stage 1 or 2, compared with 55.3% in England, remaining 16.5 pp below the 75.0% national ambition by 2028. Known stage was recorded for 64.3% of all registered cancers (8,209 of 12,766; England 67.0%), meaning unrecorded staging limits system comparisons. Locally, PCN breast screening coverage is 67.1% (England 69.9%, Adur 75.8%), while cervical screening in women aged 25–49 is 73.2% (England 66.8%), though coverage fell 2.4% over three years (England -1.0%). Lower screening uptake may delay early detection across local practices.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In Jul 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the cancer 62-day referral to treatment standard, trailing East Sussex Healthcare NHS Trust (67.0%), Surrey and Sussex Healthcare NHS Trust (70.0%), England (71.2%) and NHS Surrey and Sussex Integrated Care Board (71.5%), sitting 19.8 pp below the 85.0% standard. The trust reached 74.0% on the 28-day faster diagnosis standard (England 79.3%). For diagnostics, 12.9% waited 6+ weeks across all diagnostic tests (England 23.1%), though colonoscopy waits reached 39.3% (England 30.8%) and flexi sigmoidoscopy reached 45.4% (England 32.1%).

    Pathways within standard (%)SussexEast Sussex HealthcareSurrey and Sussex HealthcareSurrey and Sussex ICBEngland
    28-day faster diagnosis (75%)74.0184.2077.7479.2979.32
    31-day treatment (96%)76.7998.1996.2090.4592.50
    62-day referral to treatment (85%)65.2067.0469.9771.5171.16
    Diagnostic waits over 6 weeks (%)SussexEast Sussex HealthcareSurrey and Sussex HealthcareEngland
    MRI5.626.4827.5321.40
    CT8.570.4818.499.92
    Echocardiography0.3921.9443.7828.48
    Colonoscopy39.350.7415.1130.83
    Gastroscopy20.020.3121.0629.02
    All 15 DM01 tests12.955.2728.5023.14
    Community services activityWest Sussex residentsSurrey and Sussex ICB
    Care contacts78,050309,615
    Referrals16,01566,930
    Patients with a contact19,77085,660

    Community services (residents of West Sussex), Jun 2026 (provisional). In Jun 2026, experimental community data recorded 115,485 care activities and 78,050 care contacts for West Sussex residents, alongside 316,320 activities and 309,615 contacts across NHS Surrey and Sussex Integrated Care Board. Adults aged 65+ accounted for 72.7% of West Sussex contacts (56,740 of 78,050). These provisional counts cover submitting providers only and describe local authority and system activity rather than unique PCN patients.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Overall patient experience ranges from 47.2% to 83.4% across the three constituent practices

    In 2025/26, all three practices attained 100.0% in QOF clinical-domain achievement (England 97.1%). Overall QOF achievement reached 96.7% at Ball Tree Surgery, 97.2% at New Pond Row Surgery, and 100.0% at The Orchard Surgery. Conversely, vaccination and immunisation achievement exhibited a 28.5 pp inter-practice range, varying from 71.5% at Ball Tree Surgery to 100.0% at The Orchard Surgery.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Ball Tree Surgery1230.036.7%74.2%83.4%
    Orchard1100.042.4%86.3%70.9%
    New Pond Row910.014.2%54.3%47.2%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNAdurAssetPCNAdur
    Care homes (catchment)7 (245 beds)n/aSchools (catchment)22n/a
    Children's centres24Places of worship1229
    Libraries13Homelessness support (VCS)0no data
    Day centres (VCS)11Carers support groups (VCS)11
    Primary schools (LA maintained)15Primary academies27

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Hypertension control and recall audit

    Across 6,217 patients (21.4% prevalence), hypertension treated to target (69.9%; England 70.3%) fell 2.7% (England +3.6%); control under 80 is 67.1% (New Pond Row Surgery 58.6%). For discussion, the PCN could run a structured recall and pharmacist-led titration review for patients above BP threshold, starting at New Pond Row Surgery. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 2

    Asthma and COPD review recall

    Asthma review coverage is 63.0% (England 65.7%, Adur 60.1%) across 2,329 patients (about 860 unreviewed), while COPD reviews (75.6%; register 790) fell 4.5% (England +2.8%). For discussion, practices could standardise annual respiratory recall templates, offer flexible review slots, and check second-hand smoking recording (76.7% in ages 6-19 vs Adur 83.0%). Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 3

    CVD statin and formulary review

    Statin treatment in diabetes with CVD is 79.0% (England 84.4%), while lipid-modifying prescribing costs £4.50 per item (£123,821 more than at England's £1.86 unit cost across 46,902 items). Low cost, quick to run.

    Evidence base: the stroke/TIA register is the cohort for AF anticoagulation and blood-pressure control (pre-stroke prevention) as well as hyperacute care; practices well below expected prevalence are the case-finding list, and the pre-stroke prevention gap concentrates in deprived practices.

    Policy anchor: Core20PLUS5 (CVD); NHS CVD ambitions to 2029.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older adult care coordination (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Clinical vulnerability outreach targeting (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Severe mental illness check outreach (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension recall audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall outreach (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Practice telephony and access review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Hypertension control and recall audit (p12)Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP readingCore20PLUS5 CVD · CVDPREVENT 2029PCN & Practice
    Option 2 · Asthma and COPD review recall (p12)Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 3 · CVD statin and formulary review (p12)Stroke register · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapyCore20PLUS5 CVD · CVDPREVENT · SSNAPPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15